Change from a consolidated subsidiary of Stella Pharma Corporation to an equity-method affiliate
First written in FY2023-Q1. 3 of 5 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「Equity-method affiliate STELLA PHARMA CORPORATION Chuo-ku, Osaka 2,859 High-Purity Chemicals 33」
The Company continues to treat STELLA PHARMA CORPORATION not as a consolidated subsidiary but as an equity-method affiliate, with an ownership interest carrying 33% of the voting rights. - FY2023ReframedAnnual report
「Because STELLA PHARMA CORPORATION, which constituted the Medical business in the previous consolidated fiscal year, changed from within the scope of consolidation to within the scope of application of the equity method, the Company excluded the Medical business from its reportable segments from the current consolidated fiscal year and included it in the High-Purity Chemicals business.」
The Company continues to treat STELLA PHARMA CORPORATION as an equity-method affiliate, without reporting the Medical business's results as a separate consolidated segment, and includes them in the High-Purity Chemicals business. - FY2023-Q3RestatedAnnual report
「Because STELLA PHARMA CORPORATION, which operates the Medical business, changed from a consolidated subsidiary to an equity-method affiliate, results for this segment have not been recorded from the first quarter of the current consolidated fiscal year.」
The Company continues to treat STELLA PHARMA CORPORATION as an equity-method affiliate and does not include the Medical segment's results in the consolidated results. - FY2023-Q2RestatedAnnual report
「Because STELLA PHARMA CORPORATION, which operates the Medical business, changed from a consolidated subsidiary to an equity-method affiliate, results for this segment have not been recorded from the first quarter of the current consolidated fiscal year.」
The Company continues to treat STELLA PHARMA CORPORATION as an equity-method affiliate and does not include the Medical segment's results in the consolidated results, including in the second quarter. - FY2023-Q1First statedAnnual report
「Because STELLA PHARMA CORPORATION, which operates the Medical business, changed from a consolidated subsidiary to an equity-method affiliate, no results for this segment were recorded in the cumulative three-month period of the current consolidated fiscal year.」
Following the change in the scope of consolidation after the partial sale of STELLA PHARMA CORPORATION shares, Medical was excluded from the reportable segments, and its revenue and operating income or loss were not included in the consolidated results for the quarter.